Back to funds
View filing
Foresite Capital Management V, LLC
hedge fundUpdated 27 days agoManaged by Foresite Capital Management V, Llc • Latest filing Q2 2026
Portfolio value
$362.2M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
7.3%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $135.3M |
| Q2 2023 | $136.9M |
| Q3 2023 | $62.7M |
| Q4 2023 | $73.4M |
| Q1 2024 | $106.5M |
| Q2 2024 | $156.6M |
| Q3 2024 | $143.9M |
| Q4 2024 | $120.2M |
| Q1 2025 | $87.6M |
| Q2 2025 | $80.7M |
| Q3 2025 | $108.7M |
| Q4 2025 | $164.4M |
| Q1 2026 | $271M |
| Q2 2026 | $362.2M |
Top holdings
9 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | A ALMS ALUMIS INC. | $165.9M | 5.90M | 45.81% | — |
| 2 | C CGON CG Oncology, Inc. | $76.7M | 1.08M | 21.17% | — |
| 3 | I IRON Disc Medicine, Inc. | $27.4M | 374.1K | 7.55% | — |
| 4 | H HIMS Hims & Hers Health, Inc. | $25.6M | 738.2K | 7.07% | — |
| 5 | P PHVS Pharvaris N.V. | $23M | 664.1K | 6.34% | — |
| 6 | E EIKN Eikon Therapeutics, Inc. | $17.2M | 1.32M | 4.75% | — |
| 7 | O ODTX Odyssey Therapeutics, Inc. | $13.3M | 713.1K | 3.68% | — |
| 8 | L LYEL Lyell Immunopharma, Inc. | $6.7M | 476.4K | 1.85% | — |
| 9 | N NRIX Nurix Therapeutics, Inc. | $6.4M | 265.0K | 1.77% | — |